Neuren Pharmaceuticals Limited

ASX (AUD): Neuren Pharmaceuticals Limited (NEU)

Last Price

16.70

Today's Change

+0.22 (1.33%)

Day's Change

16.329 - 16.90

Trading Volume

332,563

Overview

Market Cap

2 Billion

Shares Outstanding

123 Million

Avg Volume

545,933

Avg Price (50 Days)

13.98

Avg Price (200 Days)

12.99

PE Ratio

15.32

EPS

1.09

Earnings Announcement

25-Aug-2025

Previous Close

16.48

Open

16.65

Day's Range

16.33 - 16.9

Year Range

8.61 - 19.77

Trading Volume

332,563

Price Change Highlight

1 Day Change

1.33%

5 Day Change

7.19%

1 Month Change

17.61%

3 Month Change

44.46%

6 Month Change

15.73%

Ytd Change

36.33%

1 Year Change

-15.91%

3 Year Change

196.10%

5 Year Change

1165.15%

10 Year Change

838.20%

Max Change

192.47%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment